Navigation Links
CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
Date:4/10/2008

atients unable to exercise adequately. The most common side effects include flushing, chest discomfort and dyspnea. Less frequent side effects reported in patients administered Adenoscan include second and third degree AV block, fatal cardiac arrest, ventricular tachycardia and nonfatal myocardial infarction. For full prescribing information, please visit http://www.adenoscan.com.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved products include Ranexa(R) (ranolazine extended- release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.

CV Therapeutics Conference Call

Company management will webcast a conference call on Friday, April 11, 2008 at 8:30 a.m. EDT, 5:30 a.m. PDT, on the company's website. To access the live webcast and corresponding slides, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6241, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, April 18, 2008. Domestic callers can access the replay by dialing (800) 642-1
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Stemline Therapeutics Raises $12.5 Million
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. Amsterdam Molecular Therapeutics Part of Next Biotech Index
4. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
5. Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
6. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
7. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
8. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
9. Mercury Therapeutics Patents Filed
10. Cell Therapeutics, Inc. Announces Filing of Form 10-K
11. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 PRC Clinical, a ... at the ACRP 2015 Global Conference and Exhibition on ... Association of Clinical Research Professionals (ACRP) Global Conference and ... focused on the conduct of clinical trials. ACRP supports ... widely recognized industry certifications. , The ACRP 2015 ...
(Date:4/21/2015)... SAN DIEGO, CA (PRWEB) April 21, 2015 ... research in a lab, or bolted to a Kessler ... sports stadium… or at the beach, the TS3-H is designed ... , Based on a brand-new state-of-the-art 5MP sensor, the TS5-H ... its predecessors, with superior imaging characteristics. , According to ...
(Date:4/20/2015)... WORTH, Texas , April 20, 2015 ... orthopedic surgeons for healing bone injuries. The orthobiologics market ... growth opportunities for its stakeholders. The global orthobiologics market ... and forecast of revenue. The global orthobiologics market was ... to reach $7,900.2 million by 2019, at a CAGR ...
(Date:4/20/2015)... DELHI , April 20, 2015 ... PI3K Targeting Supramolecular Therapeutic Using the VOLVOX Platform - ... EST  -  Supramolecular Assembly of Antibody-drug ... Cytotoxic Payload - Presented on Sunday, Apr 19, 1:00 ... leader in supramolecular therapeutic program, today announced that the ...
Breaking Biology Technology:PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2
... N.J., Dec. 2 Regado Biosciences, Inc., announced today ... position of Senior Vice President of Business Operations and ... to Regado nearly 20 years of experience in the ... management and marketing. She will report to David ...
... Endocare, Inc.,(Nasdaq: ENDO ), an ... minimally invasive technologies used by urologists and,interventional radiologists ... from leading medical institutions including Mayo Clinic,Memorial Sloan-Kettering ... School,of Medicine , among others, will present a ...
... 1 BioTrends Research Group, Inc. released its third TreatmentTrends(TM): ... ongoing studies BioTrends conducts -- TreatmentTrends(TM) : US and ... of an on-line survey completed by 200 Nephrologists from the UK, ... management of renal anemia and hyperphosphatemia. , , ...
Cached Biology Technology:Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer 238 Cryoablation Studies, Exhibits Presented at National Radiological Society Meeting 238 Cryoablation Studies, Exhibits Presented at National Radiological Society Meeting 338 Cryoablation Studies, Exhibits Presented at National Radiological Society Meeting 4European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report 2
(Date:4/21/2015)... High crime rate, increasing ... access control systems market in Saudi Arabia ... published report by TechSci Research " Saudi Arabia Access Control ... systems market in Saudi Arabia ... control systems market in the Kingdom is growing at ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
(Date:4/20/2015)... -- The announcement comes as demand for ... (GRM), Ireland,s foremost records management company, ... up an impressive track record of clients within the first ... records management sector in Dubai . As ... and employ a further eight staff members at its Irish ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... Researchers at Rice University and Penn State University have ... creating nanotubes turns them into solid, spongy, reusable blocks that ... That,s one of a range of potential innovations for ... for the first time that boron puts kinks and elbows ...
... key to treating one of the most common types ... gene called FLT3, according to new research led by ... Helen Diller Family Comprehensive Cancer Center. Published this ... validates certain activating mutations in the FLT3 gene as ...
... (Boston) An international team of researchers led ... four loci that appear to be associated with decreasing ... region of the brain that plays an important role ... an ability that patients with Alzheimer,s disease lose. The ...
Cached Biology News:Nanosponges soak up oil again and again 2Nanosponges soak up oil again and again 3An Achilles heel of AML 2An Achilles heel of AML 3BUSM researchers identify genes that influence hippocampal volume 2